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Summary
This is the report from the fifth meeting of the Harmonising Outcome Measures
for Eczema initiative (HOME V). The meeting was held on 12–14 June 2017 in
Nantes, France, with 81 participants. The main aims of the meeting were (i) to
achieve consensus over the definition of the core domain of long-term control
and how to measure it and (ii) to prioritize future areas of research for the mea-
surement of the core domain of quality of life (QoL) in children. Moderated
whole-group and small-group consensus discussions were informed by presenta-
tions of qualitative studies, systematic reviews and validation studies. Small-group
allocations were performed a priori to ensure that each group included different
stakeholders from a variety of geographical regions. Anonymous whole-group
voting was carried out using handheld electronic voting pads according to prede-
fined consensus rules. It was agreed by consensus that the long-term control
domain should include signs, symptoms, quality of life and a patient global
instrument. The group agreed that itch intensity should be measured when
assessing long-term control of eczema in addition to the frequency of itch cap-
tured by the symptoms domain. There was no recommendation of an instrument
for the core outcome domain of quality of life in children, but existing instru-
ments were assessed for face validity and feasibility, and future work that will
facilitate the recommendation of an instrument was agreed upon.
What’s already known about this topic?
• The Harmonising Outcome Measures for Eczema initiative previously agreed on
four essential domains to be included in all atopic eczema/dermatitis trials:
clinician-reported signs, patient-reported symptoms, quality of life and long-term
control.
• EASI and POEM are the recommended instruments for signs and symptoms, respec-
tively. Instruments for quality of life (in adults and children) and long-term control
have yet to be decided upon.
• Long-term control is relevant to trials of at least 3 months’ duration.
© 2018 The Authors. British Journal of Dermatology
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What does this study add?
• It was agreed that the core outcome domain of long-term control should include
signs, symptoms, quality of life and a patient global instrument.
• For the core outcome set for quality of life in children, no single instrument can
currently be recommended, but some instruments have better face validity and
feasibility.
• A clear plan was agreed on to identify instruments to measure quality of life in
children and long-term control.
The Harmonising Outcome Measures for Eczema (HOME)
initiative is an international group working together to
develop a core outcome set (COS) for clinical trials in
eczema (synonymous with atopic eczema and atopic dermati-
tis). HOME is coordinated from the Centre of Evidence Based
Dermatology, University of Nottingham, U.K. Participation in
HOME is open to anyone with an interest in outcomes for
eczema. A COS is the agreed upon minimum set of instru-
ments that should be included in all clinical trials for a par-
ticular condition.1 Use of a COS does not preclude using
other instruments; other domains and instruments can also
be included to meet the specific requirements of individual
trials. COS initiatives are active across many fields of medi-
cine and should enable better synthesis of trial data and
reduce selective outcome reporting bias.1,2
The HOME initiative follows the best current guidance on
developing a COS.2–4 Four core domains have been identi-
fied: clinician-reported signs; patient-reported symptoms;
quality of life; and long-term control. The core outcome
measurement instruments for clinician-reported signs and
patient-reported symptoms have been established: the Eczema
Area and Severity Index (EASI) for measuring clinician-
reported signs was agreed on at the HOME III meeting,5,6
and the Patient-Oriented Eczema Measure (POEM) was cho-
sen to measure patient-reported symptoms at the HOME IV
meeting.7,8
This is a report from the fifth consensus meeting of the
HOME initiative (HOME V), which was held on 12–14 June
2017 in Nantes, France. The local organizers were Sebastien
Barbarot and Jean-Francois Stalder of Nantes University Hospi-
tal, France.
Methods
Objectives
The purposes of the HOME V meeting were (i) to achieve
consensus on the definition of the core domain of long-term
control and how to measure it and (ii) to prioritize future
areas of research for the measurement of the core domain of
quality of life (QoL) in children. Future areas of research for
QoL in adults were discussed previously at HOME IV.
Study design
HOME V was a face-to-face consensus meeting using presenta-
tions of up-to-date evidence and a modified nominal group
technique including moderated whole- and small-group dis-
cussions and anonymous electronic voting. The meeting was
held at the CCI Nantes, Nantes, France from 1300 h, Monday
12 June 2017 to 1300 h, Wednesday 14 June 2017. A series
of planning meetings was held involving the HOME executive
group (Table S1; see Supporting Information) and local orga-
nizers, and a protocol outlining the aims and methods was
prepared prior to the meeting and published on the HOME
website.9 However, there was flexibility in the programme to
allow for important issues that arose to be discussed.
The meeting was chaired by Hywel Williams, and Maarten
Boers of OMERACT (http://www.omeract.org) was the inde-
pendent moderator. Each session was chaired by the lead for
that domain: Kim Thomas for long-term control and Christian
Apfelbacher for QoL in children.
Participants
The meeting was advertised via the HOME website and
through mailing lists, including the HOME membership.
Patient representatives and pharma representatives were also
personally invited by members of the HOME executive group.
The meeting was open to anyone with an interest in core out-
comes for eczema.
In total, 81 participants from 13 countries attended the
meeting. Two nonparticipating observers were also present.
The breakdown by stakeholder group is shown in Figure 1.
Meeting structure and methods
Two optional premeeting refresher/introduction sessions were
offered, one for patients, carers and patient representatives
and one for other stakeholders. The purpose was to increase
knowledge and understanding of those participating in the
consensus meeting, in order to ensure meaningful engagement
from all stakeholders, regardless of their experience of COS
development or attendance at previous HOME meetings.
Topics covered included why COSs are important, methods
© 2018 The Authors. British Journal of Dermatology
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used in COS development, explanations of findings to be pre-
sented at the main meeting and what was expected of meeting
participants.
Background information and data were presented during
the meeting and also provided in handouts. Participants
received materials and systematic review summaries prior to
the meeting so they were well informed and were required to
undertake premeeting tasks to ensure effective small-group
discussions.
A modified nominal group technique was used, in which
small-group discussions were used to ensure that the opinions
of all participants were heard. The aim was to reach consensus
within each small group before feeding back to the whole
group. Participants were allocated a priori to one of six small
groups to ensure a spread of stakeholder groups and geo-
graphical coverage in each (Table S2; see Supporting Informa-
tion). A minimum of two patients were allocated to each
small group, although due to an unplanned absence one
group included only one patient. A facilitator who remained
independent of the discussions and a note taker were nomi-
nated beforehand for each small group. After each small group
discussion, the results of each small group were collated and
presented back to the whole group for discussion and voting.
For logistical reasons the small group constitution remained
constant throughout the meeting. The materials used can be
found on the HOME website.9
Consensus rules and voting
The voting rule to achieve consensus was agreed on at HOME
II,10 and has been used at all subsequent HOME meetings.
Consensus is defined as having been reached when < 30% of
voters disagree with the statement. Consensus voting was
anonymous using electronic handsets (HM-Pro; Hypermaster,
Chennevieres-sur-Marne, France) and voting software, with
results fed back to the group in real time once each vote was
closed. All meeting participants were permitted to vote.
Results
An overview of why COSs are needed and what HOME has
achieved so far was given,5–8,10,11 and the main aims of the
meeting were summarized. The group was reminded of the
need to listen to all opinions and be flexible and open minded
to achieve consensus.
Long-term control domain session
Introduction and background
The overall objectives of this session were to agree by consen-
sus (i) what is long-term control (i.e. its definition) and what
is important to measure (i.e. which subdomains and out-
comes) and (ii) how the long-term control domain should be
measured (i.e. which instruments). Discussions were based on
data from international online focus groups with patients and
carers, an online survey of HOME clinicians and methodolo-
gists and a systematic review showing how long-term control
has been measured in published trials.12
Each small group decided on the three most important
items and factors for defining long-term control and presented
their choices to the whole group (Tables S3 and S4; see Sup-
porting Information). It was agreed by voting (Table S5; see
Supporting Information) that any items or factors not included
in the top three for any of the six groups needed no further
consideration in subsequent decisions on face validity of the
instruments (i.e. the degree to which an instrument indeed
looks to be an adequate reflection of the construct to be mea-
sured).13
The small groups then decided which (if any) instruments
they considered not feasible for inclusion in the COS (i.e.
aspects of the outcome measurement instrument that affect
the ability to implement it or interpret the results).12 These
choices were presented to the whole group (Table S6; see
Supporting Information) and it was agreed that instruments
considered not feasible for the COS by more than two small
groups would be excluded from further consideration
(Table S7 and Fig. S1; see Supporting Information).
These voting results were included in a decision matrix to
aid subsequent discussions on which instruments had adequate
face validity and were considered feasible (Table 1).
How should the long-term control domain should be
measured?
The purpose of this session was to reduce the long list of can-
didate instruments for measuring long-term control using the
decision matrix (Table 1). The populated decision matrix was
Fig 1. Breakdown of attendees by stakeholder group.
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presented and discussed. The rows in the decision matrix com-
prised the items and factors agreed on earlier as the most
important for what to measure (face validity) and the columns
comprised only those instruments considered broadly feasible.
Colour coding (green, orange and red) and symbols (+,  and
) were used in the matrix to indicate the extent to which
each instrument captures each item or factor. Each participant
was given a printed copy of this matrix for reference during
the whole-group discussion, which is summarized in Table 2.
After examining the decision matrix (Table 1), the group
noted that no single method included all of the items or factors
previously agreed on as important, no one instrument stood
out as meeting significantly more items or factors than another
and none could be automatically excluded on the grounds of
inadequate face validity. There was general support for the con-
cept of including measurement of the existing core domains as
a way of measuring long-term control. However, it was agreed
that these alone did not necessarily capture everything deemed
to be important for the domain of long-term control and that
an additional ‘global’ measure would also be required.
Further consideration of candidate instruments
The aim of this session was to consider the validation of can-
didate instruments in more detail. Presentations on candidate
instruments were followed by a whole-group discussion, sum-
marized in Table 3.
In subsequent small-group discussions, four of the six
groups considered that the existing core domains (signs,
symptoms and QoL) were not sufficient to capture the domain
of long-term control. All six groups felt that other aspects
were required to capture long-term control fully, including
intensity of itch (five of six), eczema being in an acceptable
state to the patient (three of six) and flares (two of six), and
most felt that an additional instrument would be required to
capture potentially missing aspects of long-term control that
are currently not in the existing domains (Table S8; see Sup-
porting Information). A subsequent whole-group discussion
was held, summarized in Table 4.
The existing core domains of disease severity (incorporating
signs and symptoms), QoL and intensity of itch were all voted
Table 2 Summary of discussions on candidate instruments for
measuring long-term control
Long-term control is the overall main goal of treatment, so the
domain can be viewed differently from signs, symptoms and
QoL. Although it was stated as a separate domain in the
original HOME eDelphi exercise,13 and at HOME II,9 the group
should not be constrained by previous statements when
deciding how long-term control should be measured.
• The existing core domains of signs, symptoms and QoL are
already being measured repeatedly in trials so inclusion in
the long-term control domain represents little or no
increased burden for patients or researchers. The frequency
of data collection needs to be considered and a threshold for
repeated measures of existing domains is likely to be
required.
• The group needs to consider the added value of including
anything over and above repeated measures of the existing
core domains.
• The existing three other core domains may be insufficient to
capture all aspects of long-term control. The list of agreed
items that need to be considered for face validity also sug-
gests that additional items are required to capture long-term
control fully.
• Other items considered to add value to the existing COS for
measuring long-term control were
o Itch intensity: it was agreed at the previous HOME IV
meeting that itch is an essential subdomain of symptoms.
The core instrument for symptoms (POEM) measures
frequency of itch and not intensity. The addition of the
intensity of itch is currently being studied by the symp-
toms group.
o A patient-reported holistic global assessment of the
eczema that may capture aspects of the disease not well
covered by the existing domains. Ideas suggested
included
i a general question about how has your eczema control
been;
ii a multiquestion instrument capturing different subdo-
mains of long-term control, as has been developed in
urticaria; and
iii a global question of well-controlled weeks.
• The COS has to be feasible to enable uptake, and when con-
sidering each domain, the burden of the entire COS should
be considered.
• It was difficult to discuss the feasibility of QoL specifically,
because the instrument has not yet been agreed on. It can
be assumed that as part of the selection process, whatever
instrument is recommended will be feasible to use.
• Patient-reported outcomes are sensitive enough to pick up
changes not detected by clinician-reported outcomes in
some instances and can be collected between study visits.
QoL, quality of life; COS, core outcome set; POEM, Patient-
Oriented Eczema Measure.
Table 3 Summary of whole-group discussion on validation of the
candidate instruments
• Signs-only scores such as EASI do not cover all aspects of the
disease.
• Expressing EASI scores as 50/75/90% improvement does
not give the full picture of the disease.
• Ensure the core outcome set does not measure the same
thing more than once (i.e. be aware of duplication of instru-
ments).
• Possible floor effects of experiencing no well-controlled
weeks may become less of an issue as more-effective eczema
treatments become available.
• For a binary outcome (e.g. well-controlled weeks), if the
baseline state is well controlled, then that patient can only
get worse or stay the same. This can impact on trial design
and statistical power.
EASI, Eczema Area and Severity Index.
© 2018 The Authors. British Journal of Dermatology
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as being essential to capture long-term control (Table 5).
Flares and ‘acceptable state to the patient’ were not considered
to be essential. Less than half of voters considered that the
existing domains were sufficient if used alone to capture long-
term control fully, and it was agreed that a patient ‘global’
assessment was also required (Table 5). The group discussed
this final decision against the other considerations for measur-
ing long-term control that had previously been prioritized
(Table S9; see Supporting Information).
Choice of preferred outcome instruments
Because repeated measures of existing domains had formed a
significant part of the discussions so far about ‘what’ to
measure, the existing recommended instruments had already
been discussed as part of that decision-making process. Con-
flicts of interest were declared with regards to instruments
under discussion (and can be found in the conflicts of interest
section of this report).
There were differing opinions on whether instruments other
than those already recommended for the COS should be used
to measure signs and symptoms for the long-term control
domain. Some felt that the instruments for measuring signs and
symptoms had already been decided on, and because they are
already included at multiple time points during trials, recom-
mending an additional instrument to measure the same thing
would not be appropriate. However, others felt that because
long-term control is a separate domain, other instruments
should be considered and the COS potentially expanded to
include other instruments in addition to EASI14 and POEM15
for signs and symptoms. However, there was consensus that no
further discussion was required on this issue before the group
could continue (Table 5). Therefore, discussions on alternatives
to EASI and POEM for measuring signs and symptoms in the
long-term control domain will take place subsequently to this
meeting. The group then voted and consensus was reached that
the existing instruments (EASI and POEM) should be recom-
mended ‘for the time being’ for measuring long-term control
(Table 5). It was not possible to include QoL in this vote as the
instrument has not yet been agreed upon.
Future work
The group agreed with a nonanonymous vote (show of
hands) that the following should be the priority and focus for
work subsequently to this meeting:
• For the holistic ‘patient global’ outcome measure: deter-
mine what is already available and, if necessary, develop a
new instrument. Consider a truly global measurement
instrument (single question) vs. a multi-item instrument
(such as that developed for urticaria).16 Set up a dedicated
Table 4 Summary of whole-group discussion on capturing long-term
control
• Existing domains were sufficient to capture ‘flares’, but a
patient-reported holistic global assessment may also be
required to capture fully part of the long-term control
domain, which can be hard to define.
• Including some kind of global measure would cover some
of the overall impact of eczema.
• Global assessments tend to be sensitive to change.
• PO-SCORAD adds value to the existing core set by adding
itch intensity, which is not captured by the existing symp-
toms-domain instrument POEM. Using PO-SCORAD may
reduce the need for an additional instrument to capture itch
intensity.
• Including PO-SCORAD in addition to POEM may result in
duplication, as the two instruments measure similar aspects
of disease symptoms.
• A show of hands indicated that the vast majority considered
that intensity of itch should be included in the long-term
control domain.
PO-SCORAD, Patient-Oriented Scoring Atopic Dermatitis; POEM,
Patient-Oriented Eczema Measure.
Table 5 Voting on the long-term control domain
Yes No Unsure
Is measuring disease severity (signs and symptoms) essential for long-term control? 93% 4% 3%
Is measuring quality of life essential for long-term control? 89% 8% 4%
Is measuring intensity of itch essential for long-term control? 80% 19% 1%
Is measuring flares essential for long-term control? 49% 42% 9%
Is measuring the acceptable state of eczema to the patient essential for long-term control? 53% 40% 7%
Is long-term control sufficiently captured by the domains of signs, symptoms (including intensity of itch) and QoL? 46% 50% 4%
Would a patient-generated global measure help capture what is missing from signs, symptoms (including intensity
of itch) and QoL?
82% 10% 7%
Should long-term control (in trials of at least 3 months) be defined by signs, symptoms, QoL and a patient global
measure?
91% 4% 4%
Is further discussion required before continuing with the long-term control domain discussion? 49% 49% 3%
Should EASI be recommended ‘for the time being’ to measure signs in the long-term control domain? 78% 19% 3%
Should POEM be recommended ‘for the time being’ to measure symptoms in the long-term control domain? 87% 13% 0%
Breakdown of voters by stakeholder group: patients 15%, clinicians 52%, methodologists 9%, pharma industry 25%. QoL, quality of life;
EASI, Eczema Area and Severity Index; POEM, Patient-Oriented Eczema Measure.
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working group and draw on how other groups have
approached this issue (e.g. OMERACT).
• Continue work already underway by the symptoms group
on the value of including intensity of itch.
• Determine thresholds for what could be considered as
‘control’ on the agreed instruments.
• At the HOME V meeting there was insufficient time to dis-
cuss in detail the frequency of measurement. It was
recommended to continue work currently underway to
determine the optimal frequency or total number of mea-
surements required and to move forward using the e-Del-
phi technique.
Quality-of-life domain (in children) session
Introduction and background
The concept of QoL was introduced as a more complex con-
struct than the other domains, requiring more questionnaire
items. More than one instrument is required to cover all age
groups, as many are designed for only a restricted age group. A
systematic review of the quality of instruments used for measur-
ing QoL in infants, children and adolescents (hereafter referred
to as children) with eczema was presented.17 The aim of the ses-
sion was to decide where to focus future research efforts based
on the face validity and feasibility of the instruments.
Face validity and feasibility of candidate quality-of-life
instruments
Each small group ranked the candidate instruments in order of
preference, based on face validity and feasibility for proxy and
self-reported instruments (Tables S10 and S11; see Supporting
Information). The overall ranking of instruments based on the
small-group results was presented to the whole group
(Table 6).
Some of the reasons were discussed among the whole
group. There was a general dislike of negatively worded ques-
tions and long recall periods (it may be difficult to remember
even a week or a month ago). Many felt the family perspec-
tive should be captured.
Regarding specific instruments, patients found the use of a
dog in the pictures in the Children’s Dermatology Life Quality
Index (CDLQI) inappropriate. In some cultures, dogs are gen-
erally regarded as a negative image, and in other cultures,
children are often teased for ‘having fleas’ due to scratching
because of their eczema. Additionally, many children with
eczema are allergic to dogs. The name ‘DISABKIDS’ was gener-
ally disliked as children are not disabled because they have
eczema. ADQoL (Atopic Dermatitis Quality of Life) was con-
sidered to be far too generic, and, despite the name, the ques-
tions were not considered to be related to having eczema. The
CADIS (Childhood Atopic Dermatitis Impact Scale) was far too
lengthy to complete and was perceived as having particularly
negative wording. The KINDL-R translation appeared poor and
would need improving.
Discussions
A whole-group discussion initially focused on whether the
group of instruments including CDLQI and Infant’s Dermatitis
Quality of Life Index (IDQoL) (and DLQI for adults) could be
recommended. Some meeting participants strongly supported
the inclusion of these instruments, but systematic reviews have
highlighted some weaknesses and many areas lack validation
studies. It was pointed out that legacy instruments would have
been developed using standards of the time and so may not
meet modern instrument development standards, and part of
COS development should be about raising the standards of
instruments. If an instrument does not meet content and struc-
tural validity then it could be considered to be fundamentally
flawed and therefore not recommended.4 Recommending any
instrument for the core set is likely to lead to an increase in
the use of that instrument, and recommending flawed instru-
ments could potentially damage the reputation of the HOME
initiative. However, the practical aspects of the COS also need
to be considered. For instance, where an instrument (or group
of instruments such as DLQI, IDQoL and CDLQI) is already
embedded in trials, clinical practice, reimbursement and treat-
ment decision making, this could be considered an argument
for inclusion in the core set despite possible inadequacies.
While there is no recommended instrument, trialists will
continue to measure QoL in many different ways, which is an
unsatisfactory situation. A number of potential suggestions
were made for future potential ways forward. Short-term solu-
tions could be (i) to accept an instrument rated as poor in the
interim because no better option is available, as has been done
by OMERACT in some instances, although it was recognized
that it can be difficult then to change this recommendation at
Table 6 Overall ranking of each quality-of-life instrument across the
six small groups
Rank Proxy instruments
1 Infant’s Dermatitis Quality of Life Index (IDQoL)
2 KINDL-R Neurodermatitis Module
3 DISABKIDS Atopic Dermatitis Module
4 Childhood Atopic Dermatitis Impact Scale (CADIS)
5 Atopic Dermatitis Quality of Life (ADQoL)
6 Childhood Impact of Atopic Dermatitis (CIAD)a
Rank Self-reported instruments
1 Children’s Dermatology Life Quality Index (CDLQI)
2 Skindex Teen
3 Children’s Dermatology Life Quality Index (CDLQI)
cartoon version
4 KINDL-R Neurodermatitis Module
5 DISABKIDS Atopic Dermatitis Module
aAlthough the CIAD was included in the review as validation
studies have been published, it was not possible, despite multi-
ple attempts, to obtain a copy. For this reason, it was considered
not feasible by all small groups.
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a later date and (ii) to recommend a nondermatology-specific
instrument in the interim until a good-quality dermatology-
specific instrument can be recommended. It was suggested
that in the longer term the group should consider developing
an entirely new instrument given that validation studies can
be lengthy. Also, the use of a family impact instrument, if a
suitable instrument can be identified, would be a way to over-
come the problem of using different instruments for different
ages.
Future work
It was agreed by voting (Table S12; see Supporting Informa-
tion) that future research on proxy and self-reported instru-
ments should be prioritized in accordance with Table 6.
Overall summary and conclusions
For the long-term control domain, the group initially populated
a decision matrix with important items and factors considered
important (to inform face validity) and instruments that were
considered feasible. Inadequate face validity and lack of feasibil-
ity are valid reasons for rejection as a candidate instrument for
the COS.4 Although the concepts overlapped at times, they nev-
ertheless provided a useful basis on which to progress the dis-
cussions and vote on what was essential to include. The group
agreed that signs, symptoms and QoL were essential but alone
were not sufficient to capture long-term control fully. Itch
intensity should be measured, as well as a patient global mea-
sure, which may capture aspects of the disease not well covered
by the existing domains. There was clear consensus to use the
existing core outcome measurement instruments for signs and
symptoms (EASI and POEM) for the time being.
Whether long-term control is a domain in its own right or
simply a time function of the other core outcomes was dis-
cussed in depth during the small- and whole-group sessions
when considering the inclusion of the existing domains.
Long-term control was considered to be a time function of
other core outcomes, as well as requiring further domains
(intensity of itch and the patient global measure), and remains
a domain to be measured in the COS for all future eczema tri-
als. However, the nature of the domain inevitably means that
other domains (signs, symptoms and QoL) become ‘subdo-
mains’ when discussed as part of long-term control.
With regards to QoL in children, because there were many
gaps in the assessment of the quality of existing QoL instru-
ments for children, the meeting focused on assessing the face
validity and feasibility of candidate instruments. Recommend-
ing an existing instrument with adequate face validity and fea-
sibility was not supported. The need for different instruments
for different age groups further complicates the decision on
which instrument to recommend. There was clear steering
from the group as to the future priorities for the QoL working
group.
Overall, the HOME V meeting has moved the HOME initia-
tive substantially further forward towards a complete COS for
eczema trials. There is still work to be done but the direction
and priority areas are agreed on and clear.
Strengths and weaknesses
There was good stakeholder representation, including patients,
with participants from several continents. However, there were
no participants from large countries such as India and China.
Despite repeated efforts, we were unable to attract regulatory
agency representation. Additionally, as the meeting was held
during school term time, there were no children present,
which was an issue for the discussions around QoL in children.
However, some of the younger patient representatives could
clearly remember and recount childhood experiences, and we
had parents of children with eczema present. Additionally, the
premeeting focus groups and survey provided a wider patient
input into the meeting. The HOME executive group encouraged
scientists from the pharma industry to attend as it is crucial that
this stakeholder group is represented, and as a result there were
more pharma industry representatives than at previous HOME
meetings, although this has potential to affect the outcomes.
There is potential for the HOME executive group to steer the
meeting in certain directions. To mitigate this, the meeting
chair made it clear that there were no fixed preconceptions to
be fulfilled at this meeting. The evidence was presented to
facilitate discussions rather than to steer the meeting in any
particular direction. The whole-group sessions were facilitated
by an independent moderator from OMERACT with extensive
experience in COS development, and the small groups were
facilitated by either a member of the HOME executive group
or an independent moderator from OMERACT.
A small number of participants were unable to be present
for the whole meeting, but all were present for the discus-
sions for any session they voted in. Anonymous real-time vot-
ing with voting rules agreed on beforehand allowed all
participants to vote, and all votes were counted equally. Estab-
lished consensus methods were used,4 in which small- and
whole-group discussions were held, underpinned by evidence,
and there were high levels of consistency between the small-
group outputs.
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Fig S1. Graph of which instruments were not feasible for
the long-term control domain.
Table S1. HOME executive group composition.
Table S2. Composition of small groups.
Table S3. Results of small groups: what is long-term
control?
Table S4. Results of small groups: what items/factors
should be considered when measuring long-term control?
Table S5. Voting to agree on the proposed list of the most
important items and factors for long-term control.
Table S6. Results of small groups: instruments considered
not feasible for measuring long-term control in the core out-
come sets.
Table S7. Voting to agree on the proposed list of feasible
instruments for measuring long-term control.
Table S8. Results of small groups: is long-term control cap-
tured by existing domains?
Table S9. Summary of discussion and agreement regarding
the extent to which the items and factors considered to be
important when measuring long-term control are covered by
measurement of existing domains (signs, symptoms and qual-
ity of life) and a patient global measurement instrument.
Table S10. Results of small groups: quality of life in chil-
dren, proxy instruments.
Table S11. Results of small groups: quality of life in chil-
dren, self-reported instruments.
Table S12. Voting on whether the ranked order of quality-
of-life instruments should be used to prioritize further
research.
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